- Raised $8M Series B, Oct 2021
- Raised $6M Series A led by aMoon Fund, May 2020
About
Curesponse is a precision oncology company that has developed the cResponse™ platform, a cutting-edge functional platform designed to empirically match the right drug to each patient's cancer. The technology combines rapid genomic analysis with functional cancer treatment prediction within living tumor tissue, preserving the tumor's 3D structure and microenvironment. This platform aims to improve survival and reduce unnecessary medical interventions by assessing the effectiveness of chemotherapy, targeted biologics, and immunotherapy across the therapeutic spectrum. The technology originated from research at the Weizmann Institute of Science in Israel and has been calibrated using hundreds of human cancer tissues in Europe, the UK, and Israel. Curesponse collaborates with leading pharma companies, hospitals, medical centers, and payers. The company operates accredited labs in Israel and in the UK at the London Cancer Hub.
Funding history · 2 rounds · $14.0M total
Headcount over time
Q&A
- What is Curesponse's primary focus?
- Curesponse specializes in personalized medicine for accurate cancer treatment, utilizing a technology that predicts how cancer treatments will affect a patient's tumor cells in their native environment.
- What is the name of Curesponse's core technology?
- Curesponse developed cResponse, a combined Genomic-Functional assay that tests the effectiveness of selected treatments on a patient's tumor while preserving its original composition and 3D structure.
- When was Curesponse founded?
- Curesponse was founded in November 2017.
- How many employees does Curesponse have?
- Curesponse has 11-50 employees.
- What is Curesponse's total funding to date?
- Curesponse has raised a total of $14,000,000 USD.
- When was Curesponse's most recent funding round and how much was raised?
- Curesponse's most recent funding round was in November 2021, raising $8,000,000 USD.
- Which investors participated in Curesponse's June 2020 funding round?
- In June 2020, Curesponse received funding from aMoon Fund and NCL Technology Ventures.
- Who are the co-founders of Curesponse?
- The co-founders of Curesponse are Guy Neev, who serves as CEO, and Seth Salpeter, who is the CTO.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | curesponse.com/ |
|---|---|
| linkedin.com/company/18434992 | |
| facebook.com/Curesponse | |
| YouTube | youtube.com/@curesponse/featured |
Identifiers & details
| Legal name | CURESPONSE LTD |
|---|---|
| Founded | 2017 |
| Employees (exact) | 15 |
| Offices | United Kingdom |
Radar intelligence
Patents
| EPO | 1 |
|---|
Publications (Crossref)
| Works | 4 |
|---|
Web history (Wayback)
| Domain | curesponse.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515737328 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-11-05 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 11 — people (1), shares_capital (4), annual_report (5), violation (1) |
| Registered address | אופנהיימר 2 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-27 | עדכון דירקטורים-הוספת דירקטור |
| 2026-01-19 | הקצאת מניות |
| 2026-01-12 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2026-01-12 | שינוי בהרכב הון - מניות-הפחתת הון רשום |
| 2026-01-12 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2025-07-07 | דו~ח שנתי-הקצאת מניות |
| 2025-07-07 | דו~ח שנתי-עדכון כתובת |
| 2025-07-07 | דו~ח שנתי-הפחתת הון מוקצה |
| 2025-07-07 | עדכון הפרה |
| 2025-07-07 | דו~ח שנתי-הוספת דירקטור |
| 2025-07-07 | דו~ח שנתי-הגדלת הון |